Changing the standard of care for treating melanoma brain metastases
Mené sur 79 patients atteints d'un mélanome et de métastases cérébrales, cet essai de phase II évalue l'efficacité, du point de vue du taux de réponse intracrânienne en semaine 12, et la toxicité de l'ajout du nivolumab à un traitement à base d'ipilimumab
Melanoma metastasis to the CNS is a devastating event. Until recently, treatment resulted in responses only anecdotally,1,2 and median survival generally ranged 3–5 months.3 However, the COMBI-MB trial4 showed that in patients with BRAFV600E-mutated brain metastases, 44 (58%; 95% CI 46–69) of 76 patients responded to dabrafenib and trametinib combination treatment, although the median time to progression was only 5·6 months (95% CI 5·3–7·4). The results of COMBI-MB trial4 confirmed that for melanomas driven by an activating BRAF mutation, inhibition of the ERK pathway results in dramatic tumour shrinkage regardless of the site of metastasis
The Lancet Oncology , commentaire, 2017